Hikma Pharmaceuticals - HIK Share Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" HIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HIK, but not buy additional shares or sell existing shares.
View HIK analyst ratings or view top-rated stocks.

6 brokerages have issued 12-month target prices for Hikma Pharmaceuticals' stock. Their HIK share price forecasts range from GBX 1,750 to GBX 2,880. On average, they predict the company's share price to reach GBX 2,268.33 in the next twelve months. This suggests a possible upside of 66.4% from the stock's current price.
View analysts price targets for HIK or view top-rated stocks among Wall Street analysts.

Hikma Pharmaceuticals' stock was trading at GBX 2,219 on January 1st, 2022. Since then, HIK shares have decreased by 38.6% and is now trading at GBX 1,363.50.
View the best growth stocks for 2022 here.

Hikma Pharmaceuticals declared a dividend on Thursday, August 4th. Shareholders of record on Thursday, August 18th will be given a dividend of GBX 0.19 per share on Monday, September 19th. This represents a yield of 0.89%. The ex-dividend date of this dividend is Thursday, August 18th. The official announcement can be accessed at this link.
Read our dividend analysis for HIK.

Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 0.52 per share and currently has a dividend yield of 3.11%. The dividend payout ratio is 39.42%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for HIK.

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

One share of HIK stock can currently be purchased for approximately GBX 1,363.50.

Hikma Pharmaceuticals (LON:HIK) has a market capitalization of £3.00 billion and generates £2.55 billion in revenue each year.

The company employs 8,700 workers across the globe.

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at +44-20-73992760.